1. Home
  2. ARE vs TGTX Comparison

ARE vs TGTX Comparison

Compare ARE & TGTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Alexandria Real Estate Equities Inc.

ARE

Alexandria Real Estate Equities Inc.

HOLD

Current Price

$52.96

Market Cap

9.0B

Sector

Real Estate

ML Signal

HOLD

Logo TG Therapeutics Inc.

TGTX

TG Therapeutics Inc.

HOLD

Current Price

$54.56

Market Cap

7.9B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
ARE
TGTX
Founded
1994
1993
Country
United States
United States
Employees
N/A
N/A
Industry
Real Estate Investment Trusts
Biotechnology: Pharmaceutical Preparations
Sector
Real Estate
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
9.0B
7.9B
IPO Year
1997
2008

Fundamental Metrics

Financial Performance
Metric
ARE
TGTX
Price
$52.96
$54.56
Analyst Decision
Hold
Strong Buy
Analyst Count
11
5
Target Price
$56.22
$49.80
AVG Volume (30 Days)
2.1M
2.3M
Earning Date
04-27-2026
05-04-2026
Dividend Yield
11.40%
N/A
EPS Growth
N/A
1746.67
EPS
1.68
0.17
Revenue
$3,026,556,000.00
$2,785,000.00
Revenue This Year
N/A
$49.08
Revenue Next Year
$0.15
$26.69
P/E Ratio
$31.53
$323.71
Revenue Growth
N/A
N/A
52 Week Low
$39.41
$26.76
52 Week High
$88.24
$59.30

Technical Indicators

Market Signals
Indicator
ARE
TGTX
Relative Strength Index (RSI) 55.65 57.45
Support Level $48.24 $51.22
Resistance Level $55.36 $58.08
Average True Range (ATR) 1.68 2.25
MACD 0.49 0.68
Stochastic Oscillator 74.47 67.83

Price Performance

Historical Comparison
ARE
TGTX

About ARE Alexandria Real Estate Equities Inc.

Alexandria Real Estate Equities Inc is an urban office real estate investment trust (REIT). It is engaged in the business of providing space for lease to life science, agtech, and technology tenants. The company has established a market presence in key locations, including Greater Boston, the San Francisco Bay Area, New York City, San Diego, Seattle, Maryland, and Research Triangle, Texas, and Canada. The Company is a life science real estate investment trust focused on developing, redeveloping, and operating properties that provide space for lease to tenants in the life science industry.

About TGTX TG Therapeutics Inc.

TG Therapeutics Inc is a fully integrated, commercial-stage biotechnology company focused on acquiring, developing, and commercializing novel treatments for B-cell diseases. In addition to a research pipeline, TG Therapeutics has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) to treat adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, as well as approval from several regulatory agencies outside of the U.S. for BRIUMVI to treat adult patients with RMS who have active disease defined by clinical or imaging features.

Share on Social Networks: